Genentech, part of the Roche Group, has reported promising results from its Phase III IMvigor011 trial, evaluating Tecentriq (atezolizumab) as an adjuvant therapy for patients
Summit Therapeutics Inc. announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer
Galvanize Therapeutics, Inc., a medical technology company specializing in pulsed electric field (PEF) treatments for cancer and chronic lung disease, recently completed an oversubscribed $100
Caris Life Sciences, a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of
Pfizer Inc and Astellas Pharma Inc have announced encouraging early results from the Phase 3 EV-303 (KEYNOTE-905) trial. The study evaluated PADCEV (enfortumab vedotin), an
Investment to Drive Commercial Growth, Advance Single-Cell Tri-omics Capabilities and Clinical Applications Across Cancer Mission Bio, a leader in single-cell multi-omics solutions for precision medicine,
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy Amgen announced that the global
New Initiative Part of Company’s Mission to Move Organizations Across the Healthcare Ecosystem to a More Secure, Compliant, and Resilient StateSo They Can Achieve Their Mission
Leading oncology experts explain the reasons for joining a cancer clinical trial and provide information on how to make it happen. The National Comprehensive Cancer
MSInsight, an innovative start-up specializing in precision medicine in oncology, announces the successful completion of its €1.6 million seed funding round. This fundraising was carried
New research demonstrates that investing an additional 1% of GDP in public healthcare spending, where at least 40% is aimed at preventing and treating NCDs,
clinical trials dramatically underrepresent patients who live in rural areas of the United States. Less than half of US counties (42.4%) had any cancer clinical trials
